ClinicalTrials.Veeva

Menu
The trial is taking place at:
U

University of Massachusetts Chan Medical School | Medicine Department - Rheumatology Division

Veeva-enabled site

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping (EXPLORE44)

A

Avidity Biosciences

Status and phase

Enrolling
Phase 2
Phase 1

Conditions

Exon 44
Duchenne Muscular Dystrophy

Treatments

Drug: Placebo
Drug: AOC 1044

Study type

Interventional

Funder types

Industry

Identifiers

NCT05670730
AOC 1044-CS1

Details and patient eligibility

About

AOC 1044-CS1 (EXPLORE44) is a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending doses of AOC 1044 in healthy adult volunteers and participants with DMD mutations amenable to exon 44 skipping.

Part A is a single dose design with multiple cohorts (dose levels) in healthy adult volunteers.

Part B is a multiple-ascending dose design with 3 cohorts (dose levels) in participants with Duchenne.

Enrollment

64 estimated patients

Sex

Male

Ages

7 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Part A:

Key Inclusion Criteria:

  • Aged 18 to 55 years, inclusive, at the time of informed consent
  • Body mass index (BMI) of 18.5 to 32.0 kg/m2

Key Exclusion Criteria:

  • Clinically significant abnormalities in laboratory results, ECGs, or vitals
  • Current or recent use of prescription or nonprescription drugs
  • Positive drug/alcohol test at Screening or Day -1
  • Elevated blood pressure (BP) >130/80 mmHg at Screening
  • Participation in a clinical study in which an investigational product was received within 1 month of screening or 5 half-lives of the investigational product
  • Blood or plasma donation within 16 weeks of planned AOC 1044 administration Note: Other protocol defined Inclusion/Exclusion criteria may apply

Part B:

Key Inclusion Criteria:

  • Aged 7 to 27 years, inclusive, at the time of informed consent

  • Clinical diagnosis of DMD or clear onset of DMD symptoms at or before the age of 6 years

  • Confirmation of DMD gene mutation amenable to exon 44 skipping

  • Weight ≥ 23 kg

  • Ambulatory or non-ambulatory

    • Ambulatory participants: LVEF ≥50% and FVC≥50%
    • Non-ambulatory participants: LVEF ≥45% and FVC≥40%
  • PUL 2.0 entry item A ≥3

  • If on corticosteroids, stable dose for 30 days before screening and throughout the study

Key Exclusion Criteria:

  • Biceps brachii muscles unsuitable for biopsy
  • Serum hemoglobin < lower limit of normal
  • Uncontrolled hypertension or diabetes
  • Prior treatment with any cell or gene therapy
  • Prior treatment with another exon 44 skipping agent within 6 months prior to informed consent
  • Recently treated with an investigational drug
  • History of multiple drug allergies

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Quadruple Blind

64 participants in 4 patient groups, including a placebo group

AOC 1044-CS1 Part A - Single Dose Levels 1-5
Experimental group
Description:
AOC 1044 will be administered once.
Treatment:
Drug: AOC 1044
AOC 1044-CS1 Part A - Single Dose: Placebo
Placebo Comparator group
Description:
Placebo will be administered once.
Treatment:
Drug: Placebo
AOC 1044-CS1 Part B - Multiple Ascending Dose Levels 1-3
Experimental group
Description:
AOC 1044 will be administered three times.
Treatment:
Drug: AOC 1044
AOC 1044-CS1 Part B - Multiple Ascending Dose: Placebo
Placebo Comparator group
Description:
Placebo will be administered three times.
Treatment:
Drug: Placebo

Trial contacts and locations

10

Loading...

Central trial contact

Avidity Biosciences, Inc.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems